Grand Pharmaceutical Group (HKSE:00512) EBITDA Margin % : 24.46% (As of Dec. 2023)

View and export this data going back to 1995. Start your Free Trial

What is Grand Pharmaceutical Group EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Grand Pharmaceutical Group's EBITDA for the six months ended in Dec. 2023 was HK$1,110 Mil. Grand Pharmaceutical Group's Revenue for the six months ended in Dec. 2023 was HK$4,540 Mil. Therefore, Grand Pharmaceutical Group's EBITDA margin for the quarter that ended in Dec. 2023 was 24.46%.

Grand Pharmaceutical Group EBITDA Margin % Historical Data

The historical data trend for Grand Pharmaceutical Group's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Grand Pharmaceutical Group EBITDA Margin % Chart

Grand Pharmaceutical Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBITDA Margin %

Get a 7-Day Free Trial

30.04

38.98

37.43

31.89

27.94

Grand Pharmaceutical Group Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EBITDA Margin %	Get a 7-Day Free Trial															35.88	18.78	38.52	24.02	24.46

Competitive Comparison of Grand Pharmaceutical Group's EBITDA Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Grand Pharmaceutical Group's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Grand Pharmaceutical Group's EBITDA Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Grand Pharmaceutical Group's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Grand Pharmaceutical Group's EBITDA Margin % falls into.

Grand Pharmaceutical Group EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Grand Pharmaceutical Group's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	2941.552	/	10529.59
	=	27.94 %

Grand Pharmaceutical Group's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %	=	EBITDA (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	1110.412	/	4540.104
	=	24.46 %

Grand Pharmaceutical Group (HKSE:00512) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Grand Pharmaceutical Group EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Grand Pharmaceutical Group's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Grand Pharmaceutical Group (HKSE:00512) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grand Pharmaceutical Group Ltd (HKSE:00512) » Definitions » EBITDA Margin %

Traded in Other Exchanges

MX6A:Germany

Address

99 Queen's Road, Units 3302, 33rd Floor, The Center, Central, Hong Kong, HKG

Website

http://www.chinagrandpharm.com

Grand Pharmaceutical Group Ltd, formerly China Grand Pharmaceutical and Healthcare Holdings Ltd is a drug manufacturer. The company through its subsidiaries manufactures and sells pharmaceutical preparations and medical devices, biotechnology products, nutrition products, specialized pharmaceutical raw materials, and other products. Geographically, it derives a majority of revenue from China and also has a presence in America; Europe; Asia other than the PRC and others.

Executives

Shang Hai Yuan Da Chan Rong Tou Zi Guan Li You Xian Gong Si	2101 Beneficial owner
Hu Kaijun	2201 Interest of corporation controlled by you
East Ocean Capital (hong Kong) Company Limited	2101 Beneficial owner
Lion River I N.v.	2201 Interest of corporation controlled by you
Li Zhenfu	2201 Interest of corporation controlled by you
Gl Partners Capital Management Ltd.	2201 Interest of corporation controlled by you
Assicurazioni Generali Spa	2201 Interest of corporation controlled by you
Citic Group Corporation	2201 Interest of corporation controlled by you
Citic Limited	2201 Interest of corporation controlled by you
China Citic Bank Corporation Limited	2201 Interest of corporation controlled by you
Cncb (hong Kong) Investment Limited	2106 Person having a security interest in shares
Grand (hongkong) International Investments Holdings Limited
Chau Tung
Zhong Guo Yuan Da Ji Tuan You Xian Ze Ren Gong Si
Outwit Investments Limited

Grand Pharmaceutical Group (HKSE:00512) Headlines

No Headlines